CJC-1295 vs Ibutamoren (MK-677) Oral
A side-by-side research comparison of CJC-1295 and Ibutamoren (MK-677) Oral across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 | Ibutamoren (MK-677) Oral |
|---|---|---|
| Full name | CJC-1295 (Modified GRF 1-29) | Ibutamoren Mesylate (MK-677) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Research compound |
| Mechanism | Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release. | Mimics ghrelin at the GHS-R1a receptor in the pituitary and hypothalamus, stimulating sustained GH release without suppressing natural pulsatility. Also increases appetite via ghrelin pathway activation. |
| Molecular weight | 3,368 Da (without DAC) | 528.66 Da |
| Half-life | 30 minutes (no DAC) / 8 days (with DAC) | ~24 hours |
| Bioavailability | High (SubQ) | ~60% oral |
| Typical dose | 100-300 mcg | 10-25 mg |
| Frequency | 1-3x daily (no-DAC) | Once daily (evening) |
| Route | Subcutaneous injection | Oral capsule or liquid |
CJC-1295 reported benefits
- Increased GH production
- Improved body composition
- Enhanced recovery
- Better sleep quality
- Anti-aging effects
- Fat loss
Ibutamoren (MK-677) Oral reported benefits
- Elevated IGF-1 levels
- Improved sleep quality
- Enhanced recovery
- Increased lean mass
- Better skin/hair
- Convenient oral dosing
Related comparisons
Research and educational reference only. Not medical advice.